Protocol Page


	Study ID (Protocol Number)
	CA184-201


	STUDY LOCATIONS*
	Beth Israel Deaconess Medical Center Boston, MA 02215 Recruiting	Dr. Sudarshan K. Sharma, Ltd. Hinsdale, IL 60521 Recruiting
	Dana-Farber Cancer Inst Boston, MA 02115 Recruiting	Duke University Medical Center Durham, NC 27710 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Patients
	STUDY OVERVIEW
	To assess the incidence of drug-related adverse events of Grade 3 or higher during the induction period of Ipilimumab.

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.